Last 12 months
Inside the activity.
8 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 5 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2023 Filed Jan 4, 2023 21:20 UTC |
LIEBERMAN GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000053 · zk2328963.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 16:13 UTC |
OSTROV GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000049 · zk2328961.xml · derivative · entry 1 OSTROV GERALD M · CIK 0001534739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:16 UTC |
Mayron RonDirector
|
GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000051 · zk2328962.xml · derivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:08 UTC |
Malca YonatanDirector
|
GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000047 · zk2328960.xml · derivative · entry 1 Malca Yonatan · CIK 0001904759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:05 UTC |
Ellis SeanDirector
|
GrantStock Option (right to buy · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000045 · zk2328959.xml · derivative · entry 1 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.59 | $2,360.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 5 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F4 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 4 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F3 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 3 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F2 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F1 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 34,000 | $0.57 | $19,380.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,209 Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:13 UTC |
Yaacov-Garbeli DanaChief Financial Officer
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 26,580 | $0.54 | $14,246.88 |
DisclosureSEC source: 0001178913-22-004054 · zk2228766.xml · nonDerivative · entry 2 Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By A2Z Counseling Ltd. Disclosed balance after: 56,580 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 14:13 UTC |
Toledano Miranda JayneDirector · Chief Executive Officer
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 50,000 | $0.53 | $26,585.00 |
DisclosureSEC source: 0001178913-22-003988 · zk2228743.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 14:17 UTC |
Ellis SeanDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 30,000 | $0.53 | $15,900.00 |
DisclosureSEC source: 0001178913-22-003990 · zk2228744.xml · nonDerivative · entry 1 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.5499, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:13 UTC |
Yaacov-Garbeli DanaChief Financial Officer
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 30,000 | $0.52 | $15,600.00 |
DisclosureSEC source: 0001178913-22-004054 · zk2228766.xml · nonDerivative · entry 1 Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By A2Z Counseling Ltd. Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:07 UTC |
Toledano Miranda JayneDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001178913-22-003372 · zk2227078.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 600,000 shares Expires 2032-07-15 F2 · derivative.exercise_date: This grant of options was approved by the Board on July 15, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on July 15, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:07 UTC |
Toledano Miranda JayneDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001178913-22-003372 · zk2227078.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 11, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on May 16, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:09 UTC |
Santora Arthur C IIChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001178913-22-003374 · ownership.xml · derivative · entry 1 Santora Arthur C II · CIK 0001904746 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 20,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:05 UTC |
Yaacov-Garbeli DanaChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001178913-22-003370 · ownership.xml · derivative · entry 1 Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 21:16 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 19,491 | $1.68 | $32,803.35 |
DisclosureSEC source: 0001178913-22-002762 · zk2228172.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,209 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.664 to $1.702, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 21:19 UTC |
Ellis SeanDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 14,900 | $1.64 | $24,406.20 |
DisclosureSEC source: 0001178913-22-002765 · zk2228183.xml · nonDerivative · entry 1 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.89, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
Galitzer HillelChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001178913-22-001387 · ownership.xml · derivative · entry 1 Galitzer Hillel · CIK 0001904740 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 60,000 shares Expires 2032-03-31 F1 · derivative.exercise_date: The options vest over a four-year period that commenced on March 31, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:17 UTC |
Schwartz PhillipDirector · President of R&D
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 10,000 | $2.53 | $25,250.00 |
DisclosureSEC source: 0001178913-22-000219 · zk2227104.xml · nonDerivative · entry 1 Schwartz Phillip · CIK 0001766208 · Director · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,410 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.49 to $2.56, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| January 19, 2022 Filed Jan 24, 2022 21:21 UTC |
Ratan RameshU.S.based CFO
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 10,000 | $2.44 | $24,364.00 |
DisclosureSEC source: 0001178913-22-000223 · zk2227106.xml · nonDerivative · entry 1 Ratan Ramesh · CIK 0001904736 · U.S.based CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.44, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:07 UTC |
Mayron RonDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 7,000 | $2.80 | $19,600.00 |
DisclosureSEC source: 0001178913-22-000167 · zk2227079.xml · nonDerivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:02 UTC |
Ellis SeanDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 10,000 | $2.81 | $28,050.00 |
DisclosureSEC source: 0001178913-22-000163 · zk2227077.xml · nonDerivative · entry 1 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.80 to $2.85, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 16:19 UTC |
JAMAS SPIROSChief Executive Officer
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0001178913-22-000221 · zk2227105.xml · nonDerivative · entry 1 JAMAS SPIROS · CIK 0000903072 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.84 to $2.98, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.81 | $1,965.81 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 4 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F4 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.78 | $1,949.36 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 3 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F3 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.81 | $1,964.27 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F2 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC |
LIEBERMAN GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.80 | $1,960.21 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F1 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 21:04 UTC |
Toledano Miranda JayneDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 6,800 | $2.79 | $18,971.32 |
DisclosureSEC source: 0001178913-22-000165 · zk2227078.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 21:01 UTC |
Malca YonatanDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 7,232 | $2.74 | $19,815.68 |
DisclosureSEC source: 0001178913-22-000153 · ownership.xml · nonDerivative · entry 1 Malca Yonatan · CIK 0001904759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,232 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.73 to $2.75, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| January 13, 2022 Filed Jan 25, 2022 08:46 UTC |
OSTROV GERALD MDirector
|
PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 10,000 | $2.74 | $27,378.00 |
DisclosureSEC source: 0001178913-22-000229 · ownership.xml · nonDerivative · entry 1 OSTROV GERALD M · CIK 0001534739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:12 UTC |
Toledano Miranda JayneDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000095 · zk2227047.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:12 UTC |
Toledano Miranda JayneDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000095 · zk2227047.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:08 UTC |
GARCEAU ROGERDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000089 · zk2227044.xml · derivative · entry 2 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:08 UTC |
GARCEAU ROGERDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000089 · zk2227044.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:10 UTC |
LIEBERMAN GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000093 · zk2227046.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:10 UTC |
LIEBERMAN GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000093 · zk2227046.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:09 UTC |
Mayron RonDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000091 · zk2227045.xml · derivative · entry 2 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:09 UTC |
Mayron RonDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000091 · zk2227045.xml · derivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 13, 2022 16:03 UTC |
OSTROV GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000109 · ownership.xml · derivative · entry 2 OSTROV GERALD M · CIK 0001534739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 13, 2022 16:03 UTC |
OSTROV GERALD MDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000109 · ownership.xml · derivative · entry 1 OSTROV GERALD M · CIK 0001534739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 14, 2022 21:04 UTC |
Ellis SeanDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000123 · zk2227062.xml · derivative · entry 2 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 14, 2022 21:04 UTC |
Ellis SeanDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000123 · zk2227062.xml · derivative · entry 1 Ellis Sean · CIK 0001904752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 14, 2022 12:06 UTC |
Malca YonatanDirector
|
GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000119 · ownership.xml · derivative · entry 2 Malca Yonatan · CIK 0001904759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 14, 2022 12:06 UTC |
Malca YonatanDirector
|
GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000119 · ownership.xml · derivative · entry 1 Malca Yonatan · CIK 0001904759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.